Overall, 33% of ER+ breast tumors were classified as having high PD-L2 levels in the malignant epithelium and 37% of ER+ breast tumors were classified as having high PD-L2 levels in stromal cells. This evidence concerns the gene PDCD1LG2 and breast neoplasm.